Capromab pendetide

Targets (1)

Identification

Name
Capromab pendetide
Accession Number
DB00089  (BTD00080, BIOD00080)
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA. Pendetide acts as a chelating agent for the radionuclide indium-111. Capromab is used to image the extent of prostate cancer.

Protein structure
Db00089
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • (111In)-Capromab pendetide
  • Indium (111In) capromab pendetide
  • Indium 111 Capromab Pendetide
  • Indium In 111 capromab pendetide
External IDs
CYT-356 / Cytogen 356
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ProstaScint Kit for the Preparation of Indium In 111 Capromab PendetideKit0.5 mg/1mLJazz Pharmaceuticals1996-10-28Not applicableUs
International/Other Brands
ProstaScint (Cytogen Corp.)
Categories
UNII
BDO5072GRX
CAS number
145464-28-4

Pharmacology

Indication

For diagnosis of prostate cancer and detection of intra-pelvic metastases.

Associated Conditions
Pharmacodynamics

Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors.

Mechanism of action

Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.

TargetActionsOrganism
AGlutamate carboxypeptidase 2
other/unknown
Humans
Absorption
Not Available
Volume of distribution
  • 4 ± 2.1 L
Protein binding
Not Available
Metabolism

Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production

Route of elimination

Approximately 10% of the administered radioisotope dose is excreted in the urine during the 72 hours following intravenous infusion.

Half life
Not Available
Clearance
  • 42 +/- 22 mL/hr
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
16-Bromoepiandrosterone16-Bromoepiandrosterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.
19-norandrostenedione19-norandrostenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent.
5-androstenedione5-androstenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent.
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Capromab pendetide.
AbituzumabThe risk or severity of adverse effects can be increased when Capromab pendetide is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Capromab pendetide.
AdecatumumabThe risk or severity of adverse effects can be increased when Capromab pendetide is combined with Adecatumumab.
AducanumabThe risk or severity of adverse effects can be increased when Capromab pendetide is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Capromab pendetide is combined with Afelimomab.
AldosteroneAldosterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Food Interactions
Not Available

References

General References
  1. Link [Link]
  2. Link [Link]
  3. Link [Link]
External Links
PubChem Substance
46506263
ChEMBL
CHEMBL2108285
Therapeutic Targets Database
DAP001049
PharmGKB
PA164745489
Wikipedia
Indium_(111In)_capromab_pendetide
ATC Codes
V09IB04 — Indium (111in) capromab pendetide
FDA label
Download (1.65 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedDiagnosticProstate Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • EUSA Pharma Inc.
Dosage forms
FormRouteStrength
Kit0.5 mg/1mL
Prices
Unit descriptionCostUnit
Prostascint kit1584.0USD kit
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)61 °C (FAB fragment), 71 °C (whole mAb)Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Details1. Glutamate carboxypeptidase 2
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Other/unknown
General Function
Tetrahydrofolyl-poly(glutamate) polymer binding
Specific Function
Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of fola...
Gene Name
FOLH1
Uniprot ID
Q04609
Uniprot Name
Glutamate carboxypeptidase 2
Molecular Weight
84330.015 Da
References
  1. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000 Sep 15;60(18):5237-43. [PubMed:11016653]
  2. Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G: Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005 Mar;3(4):230-8. [PubMed:15882479]
  3. Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol. 1998 Feb;16(1):2-12. [PubMed:9508077]
  4. Sodee DB, Ellis RJ, Samuels MA, Spirnak JP, Poole WF, Riester C, Martanovic DM, Stonecipher R, Bellon EM: Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate. 1998 Nov 1;37(3):140-8. [PubMed:9792131]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on January 02, 2019 21:22